This site is intended for healthcare professionals only

In association with the Cardiorenal Forum

  • Latest Article

    SGLT2 inhibitors versus GLP-1 receptor agonists for renal patients: does it matter?

    In the last ten years, the advent of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has been s...

  • Pharmacist considering medications

    Novel antidiabetes drugs improve composite renal outcomes

  • Close-up of surgeon's face

    Long-term outcomes after conversion to belatacept

  • ECG trace

    Increased days in hospital after RAASi reduction

  • Nephrology research highlights 2023: Implications for clinical practice

  • Whose role is it to care for this patient? The AHA’s statement on CKM syndrome

  • Science and clinical management of cardiovascular–kidney–metabolic syndrome


For the latest news and articles
Sign up to Renal Review newsletters